Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma - 28/10/20
, Jian Zhang a, ⁎
, Peng Luo a, ⁎ 
| pagine | 11 |
| Iconografia | 7 |
| Video | 0 |
| Altro | 0 |
Graphical abstract |
Highlights |
• | Find predictable biomarker to predict the prognosis of patients receiving ICIs. |
• | SCN4A gene mutations may be one of the indicators to predict the prognosis of ICIs. |
• | We illustrate the mechanism from a macroscopic and microscopic perspective. |
Abstract |
Melanoma refers to a pigmented nevus with malignant changes. The preferred treatment for primary melanoma is surgical excision and postoperative radiotherapy, but the prognosis is poor. Immune checkpoint inhibitors (ICIs) have been remarkably successful in different types of cancers, but not all cancer patients can benefit from it. Therefore, it is essential to find predictable biomarkers and improve the accuracy of treatment. In this study, we used survival analysis, gene panorama analysis, immune cell enrichment analysis, TMB analysis, and GSEA to demonstrate that SCN4A gene mutations may be used as one of the indicators to predict the prognosis of melanoma patients undergoing ICI treatment. The research further indicates that SCN4A gene mutations improve the prognosis of ICI treatment. It is hoped that the effect of SCN4A on immunogenicity and tumor immunity can be demonstrated to further suggest the effect of this gene on the efficacy of ICIs.
Il testo completo di questo articolo è disponibile in PDF.Keywords : SCN4A, TMB, DDR, Melanoma, Immune checkpoint inhibitor
Mappa
Vol 131
Articolo 110633- novembre 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
